BMC cancer · 2026
Blood circulating C228T TERT gene promoter mutation is an independent factor for the prognosis of HBV-related hepatocellular carcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Quang Trung Pham, Chau Pham, Quang Huy Duong, Xuan Hoan Nghiem, Reboud Julien, Linh Toan Nguyen, Huu Song Le, Tat Trung Ngo
Аннотация
BACKGROUND: Telomerase reverse transcriptase (TERT) promoter mutations are among the most common noncoding genetic lesions in various cancers, including hepatocellular carcinoma (HCC). The clinical and pathological implications of hepatitis B virus (HBV)-related HCC patients carrying promoter mutations are only partially resolved.
METHODS: A nested real-time PCR assay was optimized to detect C228T TERT gene promoter mutation (C228T) from plasma samples with a detection limit of 0.1%. The established assay was used to investigate the association of the C228T with the clinical presentation of HBV-related HCC patients.
RESULTS: The C228T was detected only in the HCC group (n = 40/159, 25.2%), not in the other control groups (n = 0/160). The mutation rate was significantly higher in HCC patients with low albumin concentration, increased direct bilirubin, abdominal lymphadenopathy, and portal vein thrombosis, compared with HCC patients without these factors (p < 0.05); the mutation rate also increased progressively with more advanced stages (p < 0.05) and was significantly associated with shorter overall survival (OS).
CONCLUSION: The C228T is associated with advanced stages, poorer liver function, and shorter overall survival; hence, it could be used as a novel biomarker for the prognosis of HBV-related HCC patients.
METHODS: A nested real-time PCR assay was optimized to detect C228T TERT gene promoter mutation (C228T) from plasma samples with a detection limit of 0.1%. The established assay was used to investigate the association of the C228T with the clinical presentation of HBV-related HCC patients.
RESULTS: The C228T was detected only in the HCC group (n = 40/159, 25.2%), not in the other control groups (n = 0/160). The mutation rate was significantly higher in HCC patients with low albumin concentration, increased direct bilirubin, abdominal lymphadenopathy, and portal vein thrombosis, compared with HCC patients without these factors (p < 0.05); the mutation rate also increased progressively with more advanced stages (p < 0.05) and was significantly associated with shorter overall survival (OS).
CONCLUSION: The C228T is associated with advanced stages, poorer liver function, and shorter overall survival; hence, it could be used as a novel biomarker for the prognosis of HBV-related HCC patients.